15. Inclusion body myositis Clinical trials / Disease details

Clinical trials : 42 / Drugs : 33 - (DrugBank : 11) / Drug target genes : 12 - Drug target pathways : 123

35 trials found

diseases per page:

Showing 1 to 10 of 35 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05032131 (ClinicalTrials.gov)	September 2021	27/8/2021	Cell Therapy for IBM by Muscle Injection of ADSVF: a Phase I Trial	Cell Therapy for Inclusion Body Myositis (IBM) by Muscle Injection of Autologous Uncultured Adipose- ...	Inclusion Body Myositis	Biological: ADSVF	Assistance Publique - Hôpitaux de Paris	NULL	Not yet recruiting	45 Years	80 Years	All	32	Phase 1	NULL
2	NCT04659031 (ClinicalTrials.gov)	May 25, 2021	25/11/2020	A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Pati ...	A Phase 1, Open-Label, Ascending Dose Study of ABC008 in Adult Patients With Inclusion Body Myositis ...	Inclusion Body Myositis	Drug: ABC008	Abcuro, Inc.	NULL	Recruiting	40 Years	N/A	All	30	Phase 1	Australia
3	NCT04421677 (ClinicalTrials.gov)	August 20, 2020	18/5/2020	Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis	Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis	Inclusion Body Myositis;Sporadic Inclusion Body Myositis	Drug: Phenylbutyrate Oral Tablet	University of Kansas Medical Center	NULL	Completed	18 Years	N/A	All	10	Phase 1	United States
4	EUCTR2019-000749-11-GB (EUCTR)	09/10/2019	20/06/2019	An open-label, non-randomized trial to investigate the efficacy and safety of early versus delayed s ...	An open-label, non-randomized trial to investigate the efficacy and safety of early versus delayed s ...	Sporadic Inclusion Body Myositis (sIBM) MedDRA version: 21.1;Level: LLT;Classification code 10075052 ...	Product Name: Arimoclomol Product Code: BRX-345 INN or Proposed INN: ARIMOCLOMOL Other descriptive name ...	Orphazyme A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;United Kingdom
5	NCT03710941 (ClinicalTrials.gov)	February 19, 2019	15/10/2018	Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intraveno ...	Sporadic Inclusion Body Myositis	Drug: REGN2477+REGN1033;Drug: Matching placebo	Regeneron Pharmaceuticals	NULL	Withdrawn	45 Years	75 Years	All	0	Phase 2	NULL
6	EUCTR2017-004903-33-GB (EUCTR)	18/06/2018	05/04/2018	Study of Arimoclomol in patients with Inclusion Body Myositis (IBM)	Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis (IBM)A Randomized, Double-blind, Placebo-C ...	Sporadic Inclusion Body Myositis (sIBM) MedDRA version: 21.1;Level: LLT;Classification code 10075052 ...	Product Name: Arimoclomol Product Code: BRX-345 INN or Proposed INN: ARIMOCLOMOL Other descriptive name ...	Orphazyme A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 2;Phase 3	United States;United Kingdom
7	NCT03440034 (ClinicalTrials.gov)	May 22, 2018	14/11/2017	Study of Pioglitazone in Sporadic Inclusion Body Myositis	An Open-Label Pilot Study of Pioglitazone in Sporadic Inclusion Body Myositis	Myositis;Inclusion Body Myositis;Muscular Diseases;Musculoskeletal Disease;Neuromuscular Diseases;Ne ...	Drug: Pioglitazone	Johns Hopkins University	NULL	Completed	50 Years	N/A	All	19	Phase 1	United States
8	EUCTR2015-001411-12-DK (EUCTR)	10/11/2015	11/09/2015	Extension study to evaluate the long-term efficacy, safety and tolerability of BYM338 in patients wi ...	Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tol ...	Sporadic Inclusion Body Myositis MedDRA version: 18.1;Level: PT;Classification code 10066407;Term: I ...	Product Code: BYM338 INN or Proposed INN: Bimagrumab	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 3	France;United States;Belgium;Australia;Denmark;Netherlands;Japan;Italy;United Kingdom;Switzerland
9	EUCTR2015-001411-12-BE (EUCTR)	09/11/2015	12/10/2015	Extension study to evaluate the long-term efficacy, safety and tolerability of BYM338 in patients wi ...	Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tol ...	Sporadic Inclusion Body Myositis MedDRA version: 18.0;Level: PT;Classification code 10066407;Term: I ...	Product Code: BYM338 INN or Proposed INN: Bimagrumab	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 3	France;United States;Belgium;Denmark;Australia;Netherlands;Japan;Italy;United Kingdom;Switzerland
10	EUCTR2015-001411-12-FR (EUCTR)	04/11/2015	05/08/2015	Extension study to evaluate the long-term efficacy, safety and tolerability of BYM338 in patients wi ...	Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tol ...	Sporadic Inclusion Body Myositis MedDRA version: 18.0;Level: PT;Classification code 10066407;Term: I ...	Product Code: BYM338 INN or Proposed INN: Bimagrumab	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 3	United States;France;Belgium;Denmark;Australia;Netherlands;Japan;Italy;United Kingdom;Switzerland

First Previous1 2 3 4Next Last